In lat­est set­back, an­oth­er Co­herus part­ner bails out on Am­gen biosim­i­lar deal

Just days af­ter Co­herus $CHRS was forced to re­struc­ture and lay off 51 staffers in the wake of the FDA’s de­ci­sion to re­ject its ap­pli­ca­tion for a biosim­i­lar of Am­gen’s Neu­las­ta, its Japan­ese part­ner on the num­ber-two pro­gram in the pipeline is bail­ing out of their col­lab­o­ra­tion.

Dai­ichi Sankyo says that their Phase III pro­gram for CHS-0214 hit the end­point on equiv­a­len­cy with En­brel in treat­ing rheuma­toid arthri­tis. But:

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN